VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Healthy Volunteers                                 │ Healthy Volunteers                                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age of at least 18 years                           │ Age of at least 18 years                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Existence of a contraceptive method for women of   │ Existence of a contraceptive method for women of   │     100 │
│ child-bearing age                                  │ child-bearing age                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Person affiliated to social security or            │ Person affiliated to social security or            │     100 │
│ beneficiary of such a scheme                       │ beneficiary of such a scheme                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Signed consent form                                │ Signed consent form                                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Systemic sclerosis patients                        │ Systemic sclerosis patients                        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Systemic sclerosis meeting the EULAR criteria      │ Systemic sclerosis meeting the EULAR criteria      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ulcers whose major axis measured with the          │ Ulcers whose major axis measured with the          │     100 │
│ electronic caliper is ≥ 2 mm                       │ electronic caliper is ≥ 2 mm                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age greater than or equal to 18 years              │ Age greater than or equal to 18 years              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Existence of a contraceptive method for women of   │ Existence of a contraceptive method for women of   │     100 │
│ reproductive age                                   │ reproductive age                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A person who is or is a beneficiary of social      │ A person who is or is a beneficiary of social      │     100 │
│ security                                           │ security                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Informed and signed consent signed by the patient  │ Informed and signed consent signed by the patient  │     100 │
│ or his / her legal representative                  │ or his / her legal representative                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Healthy Volunteers                                 │ Healthy Volunteers                                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treprostinil contraindications: Known              │ Treprostinil contraindications: Known              │     100 │
│ hypersensitivity to treprostinil or any of the     │ hypersensitivity to treprostinil or any of the     │         │
│ excipients, Pulmonary arterial hypertension        │ excipients, Pulmonary arterial hypertension        │         │
│ related to veno-occlusive disease, Congestive      │ related to veno-occlusive disease, Congestive      │         │
│ heart failure due to severe left ventricular       │ heart failure due to severe left ventricular       │         │
│ dysfunction, Severe hepatic insufficiency (Child-  │ dysfunction, Severe hepatic insufficiency (Child-  │         │
│ Pugh stage C), Evolving gastrointestinal ulcer,    │ Pugh stage C), Evolving gastrointestinal ulcer,    │         │
│ intracranial hemorrhage, recent trauma or other    │ intracranial hemorrhage, recent trauma or other    │         │
│ clinical condition that may lead to bleeding,      │ clinical condition that may lead to bleeding,      │         │
│ Congenital or acquired valvular abnormalities with │ Congenital or acquired valvular abnormalities with │         │
│ cardiac repercussions, Severe ischemic heart       │ cardiac repercussions, Severe ischemic heart       │         │
│ disease or unstable angina; Myocardial infarction  │ disease or unstable angina; Myocardial infarction  │         │
│ in the last six months; Decompensated cardiac      │ in the last six months; Decompensated cardiac      │         │
│ insufficiency not medically controlled; Severe     │ insufficiency not medically controlled; Severe     │         │
│ arrhythmias; Cerebrovascular lesions (such as      │ arrhythmias; Cerebrovascular lesions (such as      │         │
│ transient ischemic attack, stroke) that occurred   │ transient ischemic attack, stroke) that occurred   │         │
│ within the last three months                       │ within the last three months                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Persons referred to in Articles L1121-5 to L1121-8 │ Persons referred to in Articles L1121-5 to L1121-8 │     100 │
│ of the French Public health Code: pregnant woman,  │ of the French Public health Code: pregnant woman,  │         │
│ parturient, nursing mother, person deprived of     │ parturient, nursing mother, person deprived of     │         │
│ liberty by judicial or administrative decision,    │ liberty by judicial or administrative decision,    │         │
│ person subject to a legal protection measure, can  │ person subject to a legal protection measure, can  │         │
│ not Be included in clinical trials                 │ not Be included in clinical trials                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject in an exclusion period from another study  │ Subject in an exclusion period from another study  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject who would receive more than 4500 euros of  │ Subject who would receive more than 4500 euros of  │     100 │
│ compensation due to his participation in other     │ compensation due to his participation in other     │         │
│ biomedical research in the 12 months preceding     │ biomedical research in the 12 months preceding     │         │
│ this study                                         │ this study                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Systemic sclerosis patients                        │ Systemic sclerosis patients                        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Iloprost cure carried out in the previous month or │ Iloprost cure carried out in the previous month or │     100 │
│ planned in the following month                     │ planned in the following month                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Initiation or change of dosage of bosentan,        │ Initiation or change of dosage of bosentan,        │     100 │
│ sildenafil or calcium channel blockers in the      │ sildenafil or calcium channel blockers in the      │         │
│ previous month or in the following month           │ previous month or in the following month           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Digital Sympathectomy or botulinum toxin injection │ Digital Sympathectomy or botulinum toxin injection │     100 │
│ planned in the following month                     │ planned in the following month                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinically superinfected digital ulcers            │ Clinically superinfected digital ulcers            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treprostinil contraindications: Known              │ Treprostinil contraindications: Known              │     100 │
│ hypersensitivity to treprostinil or any of the     │ hypersensitivity to treprostinil or any of the     │         │
│ excipients, Pulmonary arterial hypertension        │ excipients, Pulmonary arterial hypertension        │         │
│ related to veno-occlusive disease, Congestive      │ related to veno-occlusive disease, Congestive      │         │
│ heart failure due to severe left ventricular       │ heart failure due to severe left ventricular       │         │
│ dysfunction, Severe hepatic insufficiency (Child-  │ dysfunction, Severe hepatic insufficiency (Child-  │         │
│ Pugh stage C), Evolving gastrointestinal ulcer,    │ Pugh stage C), Evolving gastrointestinal ulcer,    │         │
│ intracranial hemorrhage, recent trauma or other    │ intracranial hemorrhage, recent trauma or other    │         │
│ clinical condition that may lead to bleeding,      │ clinical condition that may lead to bleeding,      │         │
│ Congenital or acquired valvular abnormalities with │ Congenital or acquired valvular abnormalities with │         │
│ cardiac repercussions, Severe ischemic heart       │ cardiac repercussions, Severe ischemic heart       │         │
│ disease or unstable angina; Myocardial infarction  │ disease or unstable angina; Myocardial infarction  │         │
│ in the last six months; Decompensated cardiac      │ in the last six months; Decompensated cardiac      │         │
│ insufficiency not medically controlled; Severe     │ insufficiency not medically controlled; Severe     │         │
│ arrhythmias; Cerebrovascular lesions (such as      │ arrhythmias; Cerebrovascular lesions (such as      │         │
│ transient ischemic attack, stroke) that occurred   │ transient ischemic attack, stroke) that occurred   │         │
│ within the last three months                       │ within the last three months                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Persons referred to in Articles L1121-5 to L1121-8 │ Persons referred to in Articles L1121-5 to L1121-8 │     100 │
│ of the French Public health Code: pregnant woman,  │ of the French Public health Code: pregnant woman,  │         │
│ parturient, nursing mother, person deprived of     │ parturient, nursing mother, person deprived of     │         │
│ liberty by judicial or administrative decision,    │ liberty by judicial or administrative decision,    │         │
│ person subject to a legal protection measure, can  │ person subject to a legal protection measure, can  │         │
│ not Be included in clinical trials                 │ not Be included in clinical trials                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject in an exclusion period from another study  │ Subject in an exclusion period from another study  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject who would receive more than 4500 euros of  │ Subject who would receive more than 4500 euros of  │     100 │
│ compensation due to his participation in other     │ compensation due to his participation in other     │         │
│ biomedical research in the 12 months preceding     │ biomedical research in the 12 months preceding     │         │
│ this study                                         │ this study                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence of 1 ischemic digital cutaneous           │ Presence of at least 2 ischemic digital cutaneous  │      95 │
│ ulceration , with digital ulcer classified as      │ ulcerations on two different fingers, with digital │         │
│ "active ulcers" according to the North American    │ ulcers classified as "active ulcers" according to  │         │
│ working group definition: epithelial denudation is │ the North American working group definition:       │         │
│ clearly Visible at one place and the bed of de-    │ epithelial denudation is clearly Visible at one    │         │
│ epithelialized ulcer can be seen; Ulcerations      │ place and the bed of de-epithelialized ulcer can   │         │
│ distal to the proximal interphalangeal joint, not  │ be seen; Ulcerations distal to the proximal        │         │
│ associated with calcinosis or bony relief          │ interphalangeal joint, not associated with         │         │
│                                                    │ calcinosis or bony relief                          │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═══════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                         │   Score │
╞═══════════════════════════════════╪═══════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Age greater than or equal to 18 years │      49 │
╘═══════════════════════════════════╧═══════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 98.0
OverAll Ratio: 98.5
